Sanarus Technologies Appoints Roy Little As Chief Financial Officer

Sanarus Technologies, a heading developer of minimally invasive medical inclination for treating breast disease, currently announced a appointment of Roy Little as arch financial officer. Mr. Little is a comparison executive with some-more than forty years knowledge providing financial caring and pushing expansion for determined and startup organizations.

“Roy’s imagination goes over his financial acumen,” pronounced BJ Hardman, Chairman and CEO of Sanarus Technologies. “He’s a vital thinker whose caring and knowledge will assistance expostulate continued growth.”

Mr. Little began his career during Cigna Corporation in Philadelphia, a tellurian health word use company. Most recently, he was boss and CEO of Insurance Educational Association (IEA), where he oversaw strategy, financial and business operations, successfully heading a association by a 2008-2011 mercantile downturn.

“It’s an sparkling time to join a Sanarus team,” pronounced Mr. Little. “The cryoablation marketplace is staid for continued movement and I’m looking brazen to maximizing a intensity for growth. We’re on lane to overtake a attention by stability to rise innovative, minimally invasive diagnosis solutions that rouse a customary of care.”

Mr. Little has hold several executive and house positions with Argonaut Group, Pinkerton’s, Fireman’s Fund Insurance and ePolicy Solutions. He warranted a bachelor’s grade from Cornell University and a master of business administration from Southern Illinois University.

Sanarus Technologies revolutionized a diagnosis of early theatre breast illness and fibroadenomas with a expansion of a Visica 2™ Treatment System. The patented, FDA-cleared complement uses impassioned cold (cryo) to destroy hankie (ablation). The Visica 2 Treatment System kills a expansion by frozen it with glass nitrogen and deleterious a adjacent blood supply that fuels expansion growth.

Cryoablation offers advantages over medicine since a procession is finished underneath internal anesthesia, no breast hankie is private and a figure of a breast is maintained. Breast surgeons and interventional radiologists national are regulating this modernized record for a diagnosis of breast tumors as an choice to surgical lumpectomy.

About Sanarus Technologies

In 2001, a Visica®Treatment System was a initial complement accessible for cryoablation of fibroadenomas. Since then, a systems have been used to successfully provide thousands of patients. The System is FDA-cleared for a ablation of carcenogenic or virulent hankie and soft tumors. Since 2007, a Visica 2 Treatment System has been used to provide cancer in hundreds of cryoablation-assisted surgeries and dozens of cryoablation-only procedures in clinical trials. At Sanarus, we honour ourselves in building innovative solutions for a nonsurgical diagnosis of breast tumors. We are a woman-owned business, headquartered in Pleasanton, CA and all of a products are made in a USA. Find out some-more during

Article Original Source: Click here for details

Related Posts